Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-04-25 | "Ms. Lawton worked at various positions of increasing responsibility at Genzyme Corporation..." |
| 2014-04-07 | "Ms. Lawton... worked at various positions of increasing responsibility at Genzyme Corporation... oversaw Global Market Access..." |
| 2015-04-07 | "Ms. Lawton's qualifications to sit on the Board include significant operational, international, regulatory and senior management experience within the pharmaceutical and biotechnology industries." |
| 2016-04-08 | "The Board of Directors believes that Ms. Lawton’s qualifications to sit on the Board include significant operational, international, regulatory and senior management experience within the pharmaceutical and biotechnology industries." |
| 2017-04-10 | "Ms. Lawton has been Chief Operating Officer at Aura Biosciences... Ms. Lawton worked in various positions... at Genzyme Corporation... [including] Global Regulatory Affairs... Global Product Safety & Risk Management." |
| 2018-04-10 | "Ms. Lawton’s qualifications to sit on the Board include significant operational, international, regulatory and senior management experience within the pharmaceutical and biotechnology industries." |
| 2018-11-19 | "Alison Lawton" |
| 2019-04-08 | She is past President and Chair of the Board of Regulatory Affairs Professional Society and past FDA Advisory Committee member for the Cell and Gene Therapy Committee. She earned her B.Sc. in Pharmacology, with honors, from King’s College London. |
| 2020-04-08 | "Ms. Lawton... worked at various positions of increasing responsibility at Genzyme... Ms. Lawton earned her B.Sc. in Pharmacology, with honors, from King’s College London." |
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-20 | "She holds a B.Sc. in pharmacology from Kings College, University of London." |
| 2022-04-25 | "Ms. Lawton is an executive leader with more than 30 years experience in biopharma... She holds a B.Sc. in pharmacology from Kings College, University of London." |
| 2023-04-25 | "She holds a B.Sc. in pharmacology from Kings College, University of London." |
| 2024-04-29 | "Ms. Lawton is an executive leader with more than 35 years of experience in biopharma..." |
| 2025-03-24 | Alison Lawton (12) Consists of 51,667 shares of common stock and 12,854 shares of common stock underlying options... |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-08-25